Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GCK | P35557 | 2/20 | 0.37 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.36 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24953890 | 0.89 | CCNE1 (0.46) | MAPTCCNE1CDK2CDK5CSNK2A2 | |
| SCHEMBL24952910 | 0.86 | SCD (0.42) | MAPTKMT2AL3MBTL1 | |
| SCHEMBL24953564 | 0.86 | JAK2 (0.39) | GCK | |
| SCHEMBL24954289 | 0.85 | RAB9A (0.39) | MAPTLMNAGCKCCNE1CDK2 | |
| SCHEMBL24953934 | 0.85 | CCNE1 (0.38) | MAPTCCNE1CDK2CDK5 | |
| SCHEMBL24952962 | 0.83 | GCK (0.44) | GCKCCNE1CDK2CDK5 | |
| SCHEMBL24953737 | 0.83 | GCK (0.44) | GCKCCNE1CDK2CDK5 | |
| SCHEMBL24953935 | 0.83 | GCK (0.37) | GCKCCNE1CDK2CDK5 | |
| SCHEMBL24953916 | 0.82 | PSEN1 (0.40) | GCK | |
| SCHEMBL24952914 | 0.82 | ACACB (0.34) | GCKCCNE1CDK2CDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230029266-A1 | MrgprX2 Antagonists for the Treatment of Inflammatory Disorders | DERMIRA, INC. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230029266-A1 | MrgprX2 Antagonists for the Treatment of Inflammatory Disorders | MRGPRX2, MRGPRX1, MRGPRX4 | MAPT 3161/4885LMNA 4081/4885GCK 1519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.